MwanzoSGIOY • OTCMKTS
add
Shionogi 2 ADR Representing 1 Ord Shs
Bei iliyotangulia
$ 10.83
Bei za siku
$ 10.71 - $ 10.79
Bei za mwaka
$ 7.27 - $ 12.00
Thamani ya kampuni katika soko
3.07T JPY
Wastani wa hisa zilizouzwa
elfu 117.39
Uwiano wa bei na mapato
-
Mgao wa faida
-
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (JPY) | Des 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 147.72B | 23.48% |
Matumizi ya uendeshaji wa biashara | 48.45B | -3.83% |
Mapato halisi | 74.68B | 47.39% |
Kiwango cha faida halisi | 50.56 | 19.36% |
Mapato kwa kila hisa | — | — |
EBITDA | 80.21B | 36.44% |
Asilimia ya kodi ya mapato | 19.60% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (JPY) | Des 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 215.60B | -29.45% |
Jumla ya mali | 1.73T | 13.94% |
Jumla ya dhima | 213.60B | 38.72% |
Jumla ya hisa | 1.51T | — |
hisa zilizosalia | 850.98M | — |
Uwiano wa bei na thamani | 0.01 | — |
Faida inayotokana na mali | 11.09% | — |
Faida inayotokana mtaji | 12.36% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (JPY) | Des 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | 74.68B | 47.39% |
Pesa kutokana na shughuli | 32.03B | -21.48% |
Pesa kutokana na uwekezaji | -26.57B | -54.23% |
Pesa kutokana na ufadhili | -29.20B | -17.14% |
Mabadiliko halisi ya pesa taslimu | -18.27B | -940.68% |
Mtiririko huru wa pesa | -10.55B | -29,095.85% |
Kuhusu
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana.
Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.
In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan.
Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.
The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.
In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
1878
Makao Makuu
Tovuti
Wafanyakazi
4,955
